Fujisawa to market newly-cleared Adenoscan
This article was originally published in Clinica
Executive Summary
Medco Research (US) has received US FDA marketing approval for its Adenoscan coronary vasodilator for use in nuclear perfusion imaging. The agent, for coronary artery disease assessment in patients unable to undergo exercise stress testing, will be manufactured and marketed in North America by Fujisawa USA. The two companies have settled their respective lawsuits following a two-year legal battle in which Medco alleged that Fujisawa delayed Adenoscan's launch (see Clinica No 592, p 21). Details of the settlement were not disclosed.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.